Observational studyRheumatology international2026
Early relapse under the LoVAS reduced-dose glucocorticoid regimen in ANCA-associated vasculitis: a single-center retrospective observational study.
Observational study in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate early relapse and other clinical outcomes in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) treated with reduced-dose glucocorticoid (GC) regimens, with a focus on the LoVAS regimen in comparison with the PEXIVAS regimen. We conducted a retrospective single-center cohort study of consecutive patients with newly diagnosed or relapsing MPA or GPA treated between March 2022 and September 2025. Patients were classified into LoVAS or PEXIVAS groups if they adhered to the assigned reduced-dose GC regimens for at least 14 days. The primary outcome was time to first relapse. Secondary outcomes included time to GC withdrawal, time to serious adverse events, and cumulative GC exposure. Time-to-event outcomes were analyzed descriptively using Kaplan-Meier curves and log-rank tests and were interpreted as exploratory because of the small sample size and limited number of events. A total of 21 patients were included (LoVAS, n = 5; PEXIVAS, n = 16). Relapse occurred in 3/5 patients in the LoVAS group and 2/16 patients in the PEXIVAS group. In the LoVAS group, relapses occurred on days 21, 52, and 128 after treatment initiation. GC was withdrawn in 5/5 patients in the LoVAS group and 5/16 patients in the PEXIVAS group. Serious adverse events occurred in 3/5 patients in the LoVAS group and 7/16 patients in the PEXIVAS group. The median average daily prednisolone-equivalent dose was lower in the LoVAS group than in the PEXIVAS group: 3.06 mg/day versus 14.5 mg/day. These findings were interpreted descriptively because of the small sample size and limited number of events. These findings should be interpreted as hypothesis-generating and suggest that early relapse may occur in some patients treated with the LoVAS regimen in real-world practice. Further studies with larger cohorts and appropriate adjustment for confounding factors are needed.
Indexed as
Identifiers
42247048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.